institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 3 days ago • loading... • Updated 2 days ago

MSD Reports Phase III SMART Trial Outcomes for Infants’ RSV Risk

Summary by Clinical Trials Arena

MSD has reported new data from its Phase III SMART trial evaluating Enflonsia in infants and children under two years at increased risk for severe RSV disease.The post MSD reports Phase III SMART trial outcomes for infants’ RSV risk appeared first on Clinical Trials Arena.

3 Articles

3 Articles

Hastings Tribune

Reposted by

HealthTech HotSpot

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

RAHWAY, N.J.--(BUSINESS WIRE)--Feb 19, 2026-

3 days ago

Read Full Article

Clinical Trials Arena

MSD reports Phase III SMART trial outcomes for infants’ RSV risk

MSD has reported new data from its Phase III SMART trial evaluating Enflonsia in infants and children under two years at increased risk for severe RSV disease.The post MSD reports Phase III SMART trial outcomes for infants’ RSV risk appeared first on Clinical Trials Arena.

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources3

Leaning Left0Leaning Right0Center1Last Updated1 day agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in 3 days ago on Thursday, February 19, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics